Prestige Consumer Healthcare Inc. (NYSE:PBH) Expected to Post Q3 2026 Earnings of $1.20 Per Share

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Equities researchers at Zacks Research upped their Q3 2026 earnings per share estimates for Prestige Consumer Healthcare in a note issued to investors on Thursday, May 2nd. Zacks Research analyst R. Department now expects that the company will post earnings per share of $1.20 for the quarter, up from their prior forecast of $1.19. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.33 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s FY2026 earnings at $4.76 EPS.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, February 8th. The company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.04 by $0.02. The business had revenue of $282.74 million during the quarter, compared to analyst estimates of $280.25 million. Prestige Consumer Healthcare had a positive return on equity of 14.09% and a negative net margin of 7.11%. Prestige Consumer Healthcare’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.04 earnings per share.

A number of other research analysts have also recently issued reports on PBH. StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday, February 10th. TheStreet raised Prestige Consumer Healthcare from a “c+” rating to a “b-” rating in a research note on Monday, February 12th. One research analyst has rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $110.00.

Prestige Consumer Healthcare Price Performance

PBH stock opened at $69.95 on Monday. The firm has a market cap of $3.47 billion, a P/E ratio of -42.65, a P/E/G ratio of 1.90 and a beta of 0.53. The firm’s fifty day moving average is $71.12 and its 200 day moving average is $64.80. Prestige Consumer Healthcare has a 52 week low of $55.96 and a 52 week high of $75.31. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.92 and a current ratio of 3.09.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 5,336 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $69.00, for a total value of $368,184.00. Following the completion of the sale, the senior vice president now owns 15,934 shares in the company, valued at approximately $1,099,446. The transaction was disclosed in a document filed with the SEC, which is available at this link. 1.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Prestige Consumer Healthcare

A number of large investors have recently modified their holdings of the stock. GAMMA Investing LLC purchased a new stake in Prestige Consumer Healthcare in the fourth quarter worth about $25,000. Provence Wealth Management Group bought a new stake in shares of Prestige Consumer Healthcare during the third quarter valued at approximately $26,000. Pacer Advisors Inc. grew its stake in Prestige Consumer Healthcare by 85.7% in the fourth quarter. Pacer Advisors Inc. now owns 442 shares of the company’s stock worth $27,000 after purchasing an additional 204 shares during the period. Principal Securities Inc. bought a new position in Prestige Consumer Healthcare in the fourth quarter worth $29,000. Finally, ORG Partners LLC bought a new stake in shares of Prestige Consumer Healthcare during the 4th quarter valued at $36,000. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.